Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC62203FalcarindiolCAS: 55297-87-5纯度: >99.00% / >98.00%
Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules.
- GC62242SideroxylinCAS: 3122-87-0
Sideroxylin 是一种从 Callistemon lanceolatus 中分离的 C-甲基化黄酮,对金黄色葡萄球菌具有抗菌活性。Sideroxylin 可抑制卵巢癌细胞增殖并诱导凋亡 (apoptosis),导致 DNA 断裂,线粒体膜去极化,产生活性氧 (ROS)。
- GC62252Mefuparib hydrochlorideCAS: 1449746-00-2纯度: >98.00%
Mefuparib hydrochloride (MPH) 是一种具有口服活性的,底物竞争性和选择性的 PARP1/2 抑制剂,IC50 分别为 3.2 nM 和 1.9 nM。Mefuparib hydrochloride 诱导细胞凋亡 (apoptosis),并在体内外具有显着的抗癌活性。
- GC62253CamrelizumabCAS: 1798286-48-2纯度: >97.00% / >98.50 / >98.50% / >98.60%
卡瑞利珠单抗(Camrelizumab, 也称为SHR-1210)是一种高亲和力、人源化IgG4-κ单克隆抗体。
- GC62316Necrostatin-34CAS: 375835-43-1纯度: >98.50%
Necrostatin-34 (Nec-34) is a small molecule inhibitor of RIPK1 kinase with an IC50 of 0.13 μM in L929 cells.
- GC62319Samuraciclib trihydrochloride纯度: >99.00%
Samuraciclib (CT7001) trihydrochloride 是一种有效的,具有选择性,ATP 竞争性和口服活性的 CDK7 抑制剂,IC50 为 41 nM。Samuraciclib trihydrochloride 对 CDK7 的选择性分别是 CDK1,CDK2 (IC50 为 578 nM),CDK5 和 CDK9 的 45 倍,15 倍,230 倍和 30 倍。Samuraciclib trihydrochloride 以 GI50 值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有有效的抗肿瘤作用。
- GC62338GSK-3β inhibitor 3CAS: 1448990-73-5纯度: >98.00%
GSK-3β inhibitor 3 是一种有效,选择性,不可逆和共价的糖原合酶激酶 3β (GSK-3β) 抑制剂,IC50 值为 6.6 μM。GSK-3β inhibitor 3 可用于急性早幼粒细胞白血病的研究。
- GC62387PD-1/PD-L1-IN-9CAS: 2628506-54-5纯度: >99.00% / >99.50%
PD-1/PD-L1-IN-9是一种强效且口服有效的PD-1/PD-L1抑制剂,IC 50 值为3.8nM。
- GC62388YUM70CAS: 423145-35-1纯度: >98.00%
YUM70 is a potent inhibitor of glucose-regulated protein 78 (GRP78) inhibitor with an IC50 of 1.5 μM. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer.Although YUM70 inhibits GRP78 enzymatic activity, it increases the expression of GRP78 by increasing the chaperone translation mechanism.
- GC62400LEESGGGLVQPGGSMK acetate纯度: >99.00%
LEESGGGLVQPGGSMK acetate,一种蛋白水解肽,是 Infliximab 的一种成分,可用于 Infliximab 的定量分析。Infliximab 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。
- GC62442Casein Kinase inhibitor A51CAS: 2079068-74-7纯度: >98.00%
Casein Kinase inhibitor A51 是一种有效且具有口服活性的酪蛋白激酶 1α (CK1α) 抑制剂。Casein Kinase inhibitor A51 可诱导白血病细胞凋亡 (apoptosis),并具有有效的抗白血病活性。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC62203 | Falcarindiol | 55297-87-5 | >99.00% / >98.00% | |
Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules. | ||||
| GC62222 | DB2313 | 2170606-74-1 | >98.00% | |
DB2313是一种强效的转录因子PU.1抑制剂,IC 50 为14nM。 | ||||
| GC62242 | Sideroxylin | 3122-87-0 | - | |
Sideroxylin 是一种从 Callistemon lanceolatus 中分离的 C-甲基化黄酮,对金黄色葡萄球菌具有抗菌活性。Sideroxylin 可抑制卵巢癌细胞增殖并诱导凋亡 (apoptosis),导致 DNA 断裂,线粒体膜去极化,产生活性氧 (ROS)。 | ||||
| GC62246 | G5-7 | 939681-36-4 | >99.50% | |
G5-7 is an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. | ||||
| GC62252 | Mefuparib hydrochloride | 1449746-00-2 | >98.00% | |
Mefuparib hydrochloride (MPH) 是一种具有口服活性的,底物竞争性和选择性的 PARP1/2 抑制剂,IC50 分别为 3.2 nM 和 1.9 nM。Mefuparib hydrochloride 诱导细胞凋亡 (apoptosis),并在体内外具有显着的抗癌活性。 | ||||
| GC62253 | Camrelizumab | 1798286-48-2 | >97.00% / >98.50 / >98.50% / >98.60% | |
卡瑞利珠单抗(Camrelizumab, 也称为SHR-1210)是一种高亲和力、人源化IgG4-κ单克隆抗体。 | ||||
| GC62269 | RRD-251 | 72214-67-6 | >99.50% | |
RRD-251 是一种视网膜母细胞瘤肿瘤抑制蛋白 (Rb)-Raf-1相互作用 (Rb-Raf-1 interaction) 的抑制剂,具有高效的抗增殖、抗血管生成和抗肿瘤活性。 | ||||
| GC62316 | Necrostatin-34 | 375835-43-1 | >98.50% | |
Necrostatin-34 (Nec-34) is a small molecule inhibitor of RIPK1 kinase with an IC50 of 0.13 μM in L929 cells. | ||||
| GC62318 | SJ6986 | 2765625-93-0 | >98.50% | |
A degrader of GSPT1 and GSPT2 | ||||
| GC62319 | Samuraciclib trihydrochloride | - | >99.00% | |
Samuraciclib (CT7001) trihydrochloride 是一种有效的,具有选择性,ATP 竞争性和口服活性的 CDK7 抑制剂,IC50 为 41 nM。Samuraciclib trihydrochloride 对 CDK7 的选择性分别是 CDK1,CDK2 (IC50 为 578 nM),CDK5 和 CDK9 的 45 倍,15 倍,230 倍和 30 倍。Samuraciclib trihydrochloride 以 GI50 值为 0.2-0.3 µM 来抑制乳腺癌细胞系的生长,具有有效的抗肿瘤作用。 | ||||
| GC62322 | MS7972 | 352553-42-5 | >99.50% | |
MS7972 is a small molecule that blocks human p53 and CREB binding protein association. | ||||
| GC62338 | GSK-3β inhibitor 3 | 1448990-73-5 | >98.00% | |
GSK-3β inhibitor 3 是一种有效,选择性,不可逆和共价的糖原合酶激酶 3β (GSK-3β) 抑制剂,IC50 值为 6.6 μM。GSK-3β inhibitor 3 可用于急性早幼粒细胞白血病的研究。 | ||||
| GC62346 | UCB-9260 | 1515888-53-5 | >98.00% | |
UCB-9260 is an orally active inhibitor that inhibits TNF signalling by stabilising an asymmetric form of the trimer. UCB-9260 binds TNF with Kd of 13 ?nM. UCB-9260 also inhibits NF-κB with IC50 of 202?nM after TNF stimulation. | ||||
| GC62347 | CMC2.24 | 1255639-43-0 | >96.00% | |
CMC2.24 (TRB-N0224) 是一种口服活性三羰基甲烷制剂,通过抑制 Ras 及其下游效应子 ERK1/2 途径对小鼠胰腺肿瘤有效。CMC2.24 也是一种有效的锌依赖性 MMPs 抑制剂,IC50 范围为 2.0-69 μM。CMC2.24 通过恢复软骨内稳态和通过NF-κB/HIF-2α 轴抑制软骨细胞凋亡来减轻骨关节炎的进展。 | ||||
| GC62383 | (±)-ErSO | 2407860-40-4 | - | |
(±)-ErSO 是 ErSO 的消旋体。ErSO 是选择性预期未折叠蛋白反应 (a-UPR) 激活物。 | ||||
| GC62387 | PD-1/PD-L1-IN-9 | 2628506-54-5 | >99.00% / >99.50% | |
PD-1/PD-L1-IN-9是一种强效且口服有效的PD-1/PD-L1抑制剂,IC 50 值为3.8nM。 | ||||
| GC62388 | YUM70 | 423145-35-1 | >98.00% | |
YUM70 is a potent inhibitor of glucose-regulated protein 78 (GRP78) inhibitor with an IC50 of 1.5 μM. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer.Although YUM70 inhibits GRP78 enzymatic activity, it increases the expression of GRP78 by increasing the chaperone translation mechanism. | ||||
| GC62399 | RA375 | - | - | |
RA375 是 RPN13 (26S 蛋白酶体亚基) 抑制剂。RA375 激活 UPR 信号、ROS 产生和凋亡。RA375 的抗肿瘤活性是 RA190的 10 倍。 | ||||
| GC62400 | LEESGGGLVQPGGSMK acetate | - | >99.00% | |
LEESGGGLVQPGGSMK acetate,一种蛋白水解肽,是 Infliximab 的一种成分,可用于 Infliximab 的定量分析。Infliximab 是一种与 TNF-α 特异性结合的嵌合单克隆 IgG1 抗体。 | ||||
| GC62411 | QTX125 | 1279698-31-5 | - | |
QTX125 是一种有效且高度选择性的 HDAC6 抑制剂。与其他 HDAC 相比,QTX125 对 HDAC6 具有出色的选择性。QTX125 具有抗肿瘤作用。 | ||||
| GC62419 | Apcin-A | 1683617-62-0 | - | |
Apcin-A,是 Apcin 衍生物,是一种后期促进复合物 (APC) 抑制剂。Apcin-A 与 Cdc20 强烈相互作用,抑制 Cdc20 底物的泛素化。Apcin-A 可用于合成 PROTAC CP5V 。 | ||||
| GC62426 | ASK1-IN-2 | 2541792-70-3 | >98.00% | |
ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 32.8 nM. | ||||
| GC62442 | Casein Kinase inhibitor A51 | 2079068-74-7 | >98.00% | |
Casein Kinase inhibitor A51 是一种有效且具有口服活性的酪蛋白激酶 1α (CK1α) 抑制剂。Casein Kinase inhibitor A51 可诱导白血病细胞凋亡 (apoptosis),并具有有效的抗白血病活性。 | ||||
| GC62443 | ErSO | 2407860-35-7 | - | |
ErSO activates the anticipatory unfolded protein response (a-UPR) with an IC50 of 20.3 nM in MCF-7 cells. ErSO induces rapid and selective necrosis of ERα-positive breast cancer cell lines in vitro. | ||||
